Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 169.54M P/E - EPS this Y 91.60% Ern Qtrly Grth -
Income -86.51M Forward P/E 12.79 EPS next Y 88.20% 50D Avg Chg 23.00%
Sales 229.74M PEG -0.76 EPS past 5Y - 200D Avg Chg -57.00%
Dividend N/A Price/Book N/A EPS next 5Y 16.90% 52W High Chg -80.00%
Recommedations 2.10 Quick Ratio - Shares Outstanding 189.46M 52W Low Chg 60.00%
Insider Own 0.45% ROA - Shares Float 184.16M Beta -
Inst Own 65.93% ROE - Shares Shorted/Prior 19.87M/19.92M Price 1.79
Gross Margin 44.37% Profit Margin -37.65% Avg. Volume 2,624,620 Target Price 7.41
Oper. Margin 52.47% Earnings Date Jul 30 Volume 7,117,172 Change 5.92%
About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Esperion Therapeutics, Inc. News
05/14/24 Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
05/10/24 Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/08/24 Esperion (ESPR) Q1 Earnings Beat, Stock Up on Strong Revenues
05/08/24 Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
05/08/24 Esperion Therapeutics Inc (ESPR) Q1 2024 Earnings Call Transcript Highlights: Soaring Revenues ...
05/07/24 Heart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
05/07/24 Esperion Therapeutics Inc (ESPR) Surpasses Q1 Revenue Forecasts with a 467% Increase
05/07/24 Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
05/07/24 Esperion Reports First Quarter 2024 Financial Results
04/29/24 Esperion to Participate in Upcoming May Investor Conferences
04/25/24 These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
04/23/24 Esperion to Report First Quarter 2024 Financial Results on May 7
04/21/24 11 Best Low Price Pharma Stocks To Invest In
04/07/24 Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
04/01/24 Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
03/28/24 Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
03/26/24 Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
03/25/24 Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
03/22/24 U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
03/22/24 U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
ESPR Chatroom

User Image Hawaiianinvesta Posted - 24 minutes ago

$ESPR it's not just AMGEN but every single one of these companies should be really afraid right now. ESPR will take a lot of their PCSK9 market share that's without a doubt and fact.

User Image josh23941 Posted - 27 minutes ago

$ESPR

User Image YoloAlfred Posted - 28 minutes ago

$ESPR why not

User Image AlfredDuffel Posted - 30 minutes ago

$ESPR new post from Brinks. Take it with a few salt mines.

User Image CliffordCapital Posted - 55 minutes ago

$ESPR buckle up! 3$ by end of next week! 💯🔥♥️✅

User Image TomMac64 Posted - 1 hour ago

$ESPR How-come nobody is cursing Sheldon ?

User Image djohnson591 Posted - 1 hour ago

$ESPR Problem is if you have someone on the inside that can get you out of a predicament, than a squeeze is hard to manufacture. I'm assuming that's why it never happened here, but it happened for most of the other stocks on the squeeze list in 2021. They'll release this, when they're fully loaded.

User Image YoloAlfred Posted - 1 hour ago

$ESPR I have my yearly checkup in October if high cholesterol......I will demand Nexletol or Nexlizet.That will be one more customer and a first for me making myself profit off my own pill taking

User Image Gregg617 Posted - 1 hour ago

$ESPR I really hate to pat myself on the back because I usually get slapped in the face, but I’ll try this for the hundredth time

User Image tedevan Posted - 1 hour ago

$ESPR

User Image Gary9912 Posted - 1 hour ago

$ESPR Could you imagine if @roaringkitty saw the short sellers non sense here on this life saver!📈

User Image Sushiman12345 Posted - 1 hour ago

$ESPR My $16k at 1.48 buy is starting to look like a sexy bitch!

User Image refinedindividual Posted - 1 hour ago

$ESPR Well, I did it. Just Scheduled my physical for 5/20 and will ask to go on Nexletol. My doc has been telling me for years to go on a statin and i refused due to side effects. This is perfect for me and hoping this changes my life along with my buy at $2.20. I personally know 5 people in same statin situation and letting them know. I will update if doc actually prescribes and if my provider, which is TriCare, approves. GLTA longs. Why this isn’t a meme stock rather than games and movie theatres mystifies me. Who could short this? Oh well. Thanks for listening

User Image TagyouRit Posted - 1 hour ago

$ESPR must be an error message...for a second there I thought the price had jumped up

User Image Baruke Posted - 1 hour ago

$ESPR well this is aging well so far

User Image theDeathStar Posted - 1 hour ago

$ESPR

User Image Gregg617 Posted - 1 hour ago

$ESPR Volume just went off the hook

User Image tedevan Posted - 1 hour ago

$ESPR the 10.5 million shares is impressive. Any week the buyout could drop here.

User Image DeltaVariant Posted - 1 hour ago

$ESPR Congratz longs.

User Image Sushiman12345 Posted - 1 hour ago

$ESPR I'd love to know who the fuck loaded the boat today? Surprised Armistice didn't try and fuck this good day up in anyway.

User Image AlexLevin Posted - 1 hour ago

$ESPR do not disturb till at least 4!

User Image ejz92 Posted - 1 hour ago

$ESPR Wow, nice day, strong finish! Here’s to more days like this!

User Image refinedindividual Posted - 1 hour ago

$ESPR Can’t get a better finish in a Korean massage parlor!

User Image YoloAlfred Posted - 1 hour ago

$ESPR As much as flippers frustrate me......my revenge is knowing that some of them will feel the #1 worst feeling.......Selling something way to early and watching it run 5,000%+Trust me it haunts you

User Image llessing90 Posted - 1 hour ago

$ESPR 2.6?

User Image Midengine2021 Posted - 1 hour ago

$ESPR

User Image djohnson591 Posted - 1 hour ago

$ESPR There's always a wall, this stock is so manipulated.

User Image BullDonald Posted - 1 hour ago

$ESPR Who ever is flipping arround here for pennies .....yo mama....

User Image refinedindividual Posted - 1 hour ago

$ESPR Someone putting up a wall at $2.56. Esper is the little train that could tho- cmon u can do it!!!

User Image Ilygod Posted - 1 hour ago

$ESPR Shorts are screwed. BO will happen...oh, the price...$10-15. Who's been buying?

Analyst Ratings
HC Wainwright & Co. Buy May 8, 24
Needham Buy May 7, 24
Needham Buy Apr 10, 24
HC Wainwright & Co. Buy Mar 25, 24
Needham Buy Mar 25, 24
HC Wainwright & Co. Buy Feb 28, 24
Needham Buy Feb 27, 24
HC Wainwright & Co. Buy Nov 13, 23
Needham Buy Nov 7, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Warren Eric Chief Commercial Off.. Chief Commercial Officer Sep 20 Sell 1.245 742 924 68,318 09/21/23
Koenig Sheldon L. President and CEO President and CEO May 09 Buy 1.2596 20,000 25,192 312,816 05/10/23
Warren Eric Chief Commercial Off.. Chief Commercial Officer Mar 07 Sell 5.055 5,090 25,730 48,572 03/08/23
Koenig Sheldon L. President and CEO President and CEO Mar 07 Sell 5.056 5,441 27,510 194,815 03/08/23
Foody Joanne M. Chief Medical Office.. Chief Medical Officer Mar 07 Sell 5.065 3,884 19,672 103,060 03/08/23
Warren Eric Chief Commercial Off.. Chief Commercial Officer Aug 31 Buy 7.46 1,000 7,460 54,024 08/31/22
Koenig Sheldon L. President and CEO President and CEO Aug 05 Buy 5.8041 8,606 49,950 198,771 08/08/22
Koenig Sheldon L. President and CEO President and CEO Mar 17 Sell 4.58 571 2,615 194,717 03/18/22